Insider · CIK 0002039007
Matthew Kronmiller
Files at DMRA (Damora Therapeutics, Inc.). First filing -, latest -.
Matthew Kronmiller files SEC Form 4 as officer at DMRA (Damora Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Matthew Kronmiller has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | DMRA Damora Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +6,000 | $0.00 | $0 | 6,000 | Jan 7, 2025 |
| Oct 9, 2024 | DMRA Damora Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +8,600 | $0.00 | $0 | 8,600 | Oct 11, 2024 |
Questions about Matthew Kronmiller
Answered from the filings on this page, as of the latest one.
Is Matthew Kronmiller buying or selling?
Matthew Kronmiller has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Matthew Kronmiller's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew Kronmiller has 0.
Where does Matthew Kronmiller file Form 4?
Matthew Kronmiller has filed Form 4 at DMRA (Damora Therapeutics, Inc.) as EVP Strategy and CBO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.